Patent Description:
Tissue engineering, gene therapy, therapeutic protein production and transplantation all rely on our ability to successfully store and transport cellular material [<NUM>]. For example, in the production of recombinant therapeutic proteins, a specific cell line for each protein must be developed [<NUM>]. Given that any in vitro culture of cells will undergo phenotypic and genetic changes when propagated for long periods of time, it is neither possible nor practical to maintain a constantly-growing culture of cells [<NUM>]. The only practical solution to this is to cryopreserve cells, i.e. freezing them such that all metabolic processes stop. In particular, the ability to cryopreserve cells in monolayer format would facilitate drug development by providing phenotypically-identical cells for assays.

In order to avoid unwanted ice damage, significant volumes of cryoprotectants such as DMSO must usually be added to cells. For example, formulations containing <NUM>-<NUM>% DMSO are the standard protocol which is utilized in freezing cells in solution and in reducing cryo-injury by moderating the increase in solute concentration during freezing [<NUM>-<NUM>]. However, such concentrations are generally intrinsically toxic [<NUM>-<NUM>]. Furthermore, the repeated use of DMSO has been shown to have an impact on the epigenetic profile of cells, specifically the alteration of DNA methylation profiles, which results in phenotypic changes [<NUM>-<NUM>].

Additionally, the survival rates which are obtainable using DMSO with adherent human cells, such as embryonic stem cells, are currently too low to be of practical use [<NUM>-<NUM>].

Whilst DMSO clearly has some valuable uses in the context of cell preservation, for it to be capable of being used more widely, improvements in cell yield will have to be made in order to outweigh the issues associated with its toxicity.

A key contributor to cell death during cryopreservation is ice recrystallization (growth); this is not affected by traditional cryoprotectants and additives.

Antifreeze (glyco)proteins (AF(G)Ps) from extremophile species are potent ice recrystallization inhibitors (IRI), but are unsuitable for cryopreservation applications due to their potential toxicity/immunogenicity. Their secondary effect of dynamic ice shaping (DIS) leads to 'needle like' ice crystals which pierce cell membranes and reduce cell viability [<NUM>]. DeVries et al. [<NUM>] notes that such proteins are composed primarily of threonine, alanine, N-acetylgalactosamine and galactose; and that the results disclosed therein indicate that galactose residues, specifically their hydroxyl groups, are necessary for function.

A number of further AF(G)P sequences are disclosed in Knight et al. [<NUM>] (see Table <NUM>). Knight notes that all of these peptides had a <NUM>% alpha-helical structure, with the exception of peptide S12 which had an Ala→Pro substitution and which eliminated the antifreeze activity of the peptide. Knight also tested a number of synthetic polymers, including poly-L-histidine, poly-L-aspartic acid, poly-L-asparagine, poly-L-hydroxyproline, polyvinylalcohol (PVA), polyacrylic acid and polyvinylpyrrolidone; the best was PVA.

Synthetic polymers which have no structural similarities to AF(G)Ps but possess potent IRI properties have recently emerged as a new paradigm for controlling ice growth [<NUM>]. The most active one studied to date is poly(vinyl alcohol) (PVA), which can inhibit ice growth at less than <NUM>. mL-<NUM> and has been shown by Gibson et al. to enhance the cryopreservation of non-adherent cells [<NUM>-<NUM>]. It is hypothesized that PVA may function by recognition between the regularly-spaced hydroxyl groups and the growing ice crystal [<NUM>].

Other polymer materials have also been studied. Matsumura et al. have developed polyampholytes (mixed positive/negative charges) [<NUM>-<NUM>] which are cryoprotectants despite having only moderate IRI activity [<NUM>-<NUM>]. Wang et al. have demonstrated the significant IRI activity of graphene oxide in inhibiting the growth and recrystallisation of ice crystals in cell culture media at low concentrations [<NUM>]. have developed low molecular weight surfactants which also inhibit ice growth [<NUM>].

Whilst AF(G)Ps clearly engage specific ice crystal faces, it is clear that IRI can be engineered without affecting ice morphology, potentially by inhibiting the transfer of water between the bulk/quasi liquid layer at the ice surface [<NUM>]. Crucial to IRI is the correct display of hydrophobic groups whilst avoiding micellization/precipitation. Mitchell et al. have shown that Nisin A, a short antimicrobial peptide has pH dependent IRI activity which seems to be due to the formation of an amphipathic structure [<NUM>]. Currently, there are no crystal structures for AF(G)Ps.

In summary, therefore, a wide variety of synthetic IRIs have been previously been produced having a number of diverging structures.

The inventors have now discovered that poly(proline) has significant IRI activity and hence that it can be used for cryopreservation and in cryopreservative compositions. In contrast to the disclosures of DeVries [<NUM>] (which taught that hydroxyl groups were necessary for IRI activity), poly(proline) has now been found by the inventors to be more active than poly(hydroxyproline), with smaller MLGS (mean largest grain size) and functioning at lower concentrations. This is a significant observation as it confirms that hydroxyl groups are not essential for activity or for 'recognition' of the ice surface in IRI active compounds, and that the design of new IRI macromolecules should not be limited to poly-ols. Furthermore, there are no obvious hydrogen bond donor sites on poly(proline), which has no amide NH's.

" <NPL>" <NPL>" <CIT> discloses a glycopeptide comprising a polyproline backbone and one or more carbohydrate molecules.

It is therefore an object of the invention to provide methods and compositions which overcome one or more of the above-mentioned deficiencies.

In particular, it is an object of the invention to provide methods and compositions which prevent or inhibit ice recrystallisation in substances, e.g. biological materials and frozen food products, thereby facilitating increased cell viability in biological materials following cryopreservation and improved texture and/or flavour in frozen food products.

In one embodiment, the invention provides a method of preventing or inhibiting ice recrystallisation in a substance which is susceptible to ice crystal growth upon cryopreservation and/or warming or thawing therefrom, the method comprising the step:.

In another embodiment, the invention provides a method of cryopreserving a substance which is susceptible to ice crystal growth upon cryopreservation and/or warming or thawing therefrom, the method comprising the steps:.

In another embodiment, the invention provides a method of warming or thawing a cryopreserved substance, the method comprising the step:.

wherein the cryopreserved substance is one which has been treated with poly(proline) or a variant or derivative thereof as defined in claim <NUM>.

In another embodiment, the invention provides a method of reducing cell damage during the warming or thawing of a cryopreserved substance comprising biological material, the method comprising the step:.

The invention also provides the use of poly(proline) or a variant or derivative thereof as defined in claim <NUM> as an ice recrystallisation inhibitor.

As used herein, the term "poly(proline)" refers to a homogeneous or heterogeneous mixture of polymers which consist substantially or exclusively of linear chains of proline residues, the polymers having the general structure:
<CHM>
wherein n = <NUM>-<NUM>. The molecular mass of proline is <NUM>. Preferably, n is <NUM>-<NUM> or <NUM>-<NUM>; more preferably <NUM>-<NUM>, <NUM>-<NUM> or <NUM>-<NUM>; and even more preferably <NUM>-<NUM> or <NUM>-<NUM>. In some embodiments, n is <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM>. Most preferably, n = <NUM>.

The term "poly(proline)" includes stereoisomers of proline. In particular, the proline monomers in the poly(proline) polymers may solely be the L-proline isomer or D-proline isomer, or a mixture of the L- and D-isomers. Preferably, the proline monomers in the polyproline polymer are solely L-proline isomers or solely D-proline isomers.

Preferably, the poly(proline) polymer is a homopolymer. In other embodiments, the poly(proline) polymer is a heteropolymer. Preferably, the poly(proline) polymer consists of proline residues only.

Poly(proline) is available from Sigma Aldrich (UK) <NUM>,<NUM>-<NUM>,<NUM> mwt, <NUM>,<NUM>-<NUM>,<NUM> mwt and > <NUM>,<NUM> mwt (based on viscosities). These preferred molecular weight ranges equate to average n values of <NUM>-<NUM>, <NUM>-<NUM> and > <NUM>.

It is preferable that the poly(proline) polymer forms a poly(proline) helix, e.g. a poly(proline) I type (PPI) helix or a poly(proline) II type (PPII) helix. Most preferably, the poly(proline) polymer forms a poly(proline) II type (PPII) helix. The PPII helix is defined by (φ,ψ) backbone dihedral angles of roughly (-<NUM>°, <NUM>°) and trans isomers of the peptide bonds. For this reason, n will preferably be <NUM> or greater.

The term "poly(proline) polymer" encompasses polymers having the same or substantially the same length (i.e. wherein n has one value or substantially one value) and also mixtures of polymers wherein n is a range of values, such as those mentioned above.

The concentration of the poly(proline) polymer in the composition is preferably <NUM>-<NUM>/mL, more preferably <NUM>-<NUM>, <NUM>-<NUM> or <NUM>-<NUM>/mL. In some embodiments (e.g. for poly(proline)<NUM>), the preferred concentration is <NUM>-<NUM>/mL. In other embodiments (e.g. for poly(proline)<NUM>) the preferred concentration is <NUM>-<NUM>/mL.

The variant or derivative of the poly(proline) polymer should be one which is substantially or fully capable of forming a poly(proline) (PP) helix, preferably a poly(proline) II type (PPII) helix. The presence or absence of a poly(proline) II type (PPII) helix may be determined by circular dichroism spectroscopy.

The composition may be an aqueous composition or substantially an aqueous composition.

The composition may be a cryopreserving composition. The cryopreserving composition will, in general, be an aqueous solution, wherein water is the largest component (vol/vol). The cryopreserving composition will be one which is suitable for the preservation of biological material. Preferably, it is a physiologically-acceptable composition.

The composition may additionally comprise one or more other components. The cryopreserving composition may additionally comprise DMSO. Preferably, the amount of DMSO is <NUM>-<NUM>% (vol/vol). The cryopreserving composition may comprise no DMSO or less than <NUM>% (vol/vol) DMSO.

The cryopreserving composition may also comprise one or more other components, e.g. glycerol, trehalose, cell culture media (preferably including fetal bovine serum) and poly(ampholyte). The composition may additionally comprise one or more of the following: a buffer, e.g. PBS; an antibiotic; an anticoagulant; an antioxidant; and a pH indicator.

In a further embodiment, the invention provides a composition comprising poly(proline) or a variant or derivative thereof as defined in claim <NUM> for use in a method as claimed in any one of claims <NUM> to <NUM>, wherein
the composition comprises:.

The "substance which is susceptible to ice crystal growth upon cryopreservation and/or thawing therefrom" is preferably biological material, a food product or a personal health care product. Such substances may comprise significant quantities of water (e.g. at least <NUM>%, <NUM>% or <NUM>% water by weight) and hence ice crystals may form in such substances at cryopreserving temperatures.

As used herein, the term "biological material" relates primarily to cell-containing biological material. The term includes cells, tissues, whole organs and parts of organs.

The cells which may be used in the methods or uses of the invention may be any cells which are suitable for cryopreservation. The cells may be prokaryotic or eukaryotic cells.

The cells may be bacterial cells, fungal cells, plant cells, animal cells, preferably mammalian cells, and most preferably human cells. The cells may be all of the same type. For example, they are all blood cells, brain cells, muscle cells or heart cells.

The biological material may comprise a mixture of one or more types of cell. For example, the biological material may comprise a primary culture of cells, a heterogeneous mixture of cells or spheroids. The cells may all be from the same lineage, e.g. all haematopoietic precursor cells.

The cells for cryopreservation are generally live or viable cells or substantially all of the cells are live or viable. The cells may be isolated cells, i.e. the cells are not connected in the form of a tissue or organ.

The cells are preferably adipocytes, astrocytes, blood cells, blood-derived cells, bone marrow cells, bone osteosarcoma cells, brain astrocytoma cells, breast cancer cells, cardiac myocytes, cerebellar granule cells, chondrocytes, corneal cells, dermal papilla cells, embryonal carcinoma cells, embryo kidney cells, endothelial cells, epithelial cells, erythroleukaemic lymphoblasts, fibroblasts, foetal cells, germinal matrix cells, hepatocytes, intestinal cells, keratocytes, kidney cells, liver cells, lung cells, lymphoblasts, melanocytes, mesangial cells, meningeal cells, mesenchymal stem cells, microglial cells, neural cells, neural stem cells, neuroblastoma cells, oligodendrocytes, oligodendroglioma cells, oocytes, oral keratinocytes, organ culture cells, osteoblasts, ovarian tumour cells, pancreatic beta cells, pericytes, perineurial cells, root sheath cells, schwann cells, skeletal muscle cells, smooth muscle cells, sperm cells, stellate cells, synoviocytes, thyroid carcinoma cells, villous trophoblast cells, yolk sac carcinoma cells, oocytes, sperm or embryoid bodies; or any combination of the above.

The cells may be stem cells, for example, neural stem cells, adult stem cells, iPS cells or embryonic stem cells. The cells are preferably blood cells, e.g. red blood cells, white blood cells or blood platelets.

The cells are preferably red blood cells which are substantially free from white blood cells and/or blood platelets. In some preferred embodiments, the cells are monolayers of cells.

The method applies, inter alia, to cells grown in both 2D and 3D tissue culture, and other ways.

In other embodiments, the biological material to be cryopreserved is in the form of a tissue or a whole organ or part of an organ. The tissues and/or organs and/or parts may or may not be submerged, bathed in or perfused with the composition prior to cryopreservation.

Examples of tissues include skin grafts, corneas, ova, germinal vesicles, or sections of arteries or veins. Examples of organs include the liver, heart, kidney, lung, spleen, pancreas, or parts or sections thereof. These may be of human or non-human (e.g. non-human mammalian) origin.

The biological material or cells may preferably be selected from semen, blood cells (e.g. donor blood cells or umbilical cord blood, preferably human), stem cells, tissue samples (e.g. from tumours and histological cross sections), skin grafts, oocytes (e.g. human oocytes), embryos (e.g. those that are <NUM>, <NUM> or <NUM> cells when frozen), ovarian tissue (preferably human ovarian tissue) or plant seeds or shoots. The biological material may be living or dead (i.e. non-viable) material.

A further area in which the methods and compositions described herein find use is in food technology, specifically as texture modifiers for frozen food products.

Many frozen food products (including, but not limited to, ice cream, animal meat and fruit) suffer from the growth of ice during storage which can adversely affect the texture of the product. For example, ice cream with large crystals has a grainy texture which is unappealing, whereas meat and fruit products which have been frozen tend to lose significant volumes of water when defrosted due to ice-induced damage to the structure of the product.

Incorporation of the compositions described herein in any of these food products may be beneficial. When used in any food application, biocompatibility of the compositions is important, as well as solubility in any solution in which these may be applied to the product or in any formulation in which these may be provided.

In particular, the compositions which are described herein may be used to reduce or inhibit ice crystal growth in food products, for example during their production and/or storage in a frozen state (e.g. at a temperature of between -<NUM> and -<NUM>). Texture and flavour are typically adversely affected due to the formation of large ice crystals during the freeze-thaw cycle which takes place in most home freezers or on long term storage in the frozen state. This ice crystal growth can be minimised or even prevented entirely when using the compositions which are herein described. As a result, the texture, taste and useful storage life of frozen food products can be improved.

The compositions may be added to any food which is to be frozen until consumption or which may remain frozen during consumption and may either be incorporated throughout the entire product or, alternatively, applied only to the surface of the product which is where ice crystal growth occurs most readily. The composition may be added during conventional methods of food preparation and may be added prior to, during, or after freezing of the product. If added after freezing, this is done before the product is finally hardened so that the composition may be mixed into the product. For example, this may be incorporated into frozen foods which are intended to be consumed in the frozen state such as ice creams, frozen yoghurts, sorbets, frozen puddings, ice lollies, etc. whereby to improve mouth-feel due to the lack of large crystal formation during preparation and storage. Typically, the composition will be mixed with other ingredients during the manufacture of the products.

Other frozen food products which may benefit from the invention include frozen fruit and vegetables, such as strawberries, raspberries, blueberries, citrus fruits, pineapples, grapes, cherries, plums, peas, carrots, beans, sweetcorn, broccoli, spinach, etc..

Frozen food products which incorporate the compositions herein described and which are intended to be consumed in the frozen state and/or stored in the frozen state form a further aspect of the invention.

Preferred food products include ice cream and sorbets which will include other ingredients conventionally found in such products, such as fats, oils, sugars, thickeners, stabilisers, emulsifiers, colourings, flavourings and preservatives. In such products, the total amount of the composition will typically be at least about <NUM> wt. %, preferably at least <NUM> wt. %, e.g. about <NUM> wt. Ideal concentrations can be readily determined by those skilled in the art in the knowledge that this should be used at as low a concentration as possible whilst still having the desired effect of preventing ice recrystallisation.

As used herein, the term "treating the substance" includes, inter alia, immersing or submerging the substance in the composition or infusing or perfusing the substance with the composition such that the composition makes intimate contact with all or substantially all of the parts of the substance.

In embodiments wherein the substance is a food product, such as ice cream, the composition may be mixed with the food product.

In general, the substance will be treated with the composition prior to and/or during cryopreservation. Preferably, the substance is treated prior to cryopreservation. The substance may be cryopreserved in the composition. The substance may already be cryopreserved (i.e. at a cryopreserving temperature) before it is treated with the composition.

As used herein, the terms "cryopreserving" and "cryopreservation" refer to the storage of the substance, e.g. cells, tissues or organs, at temperatures below <NUM>.

In the context of biological material, the intention of the cryopreservation is to maintain the biological material in a preserved or dormant state, after which time the biological material is returned to a temperature above <NUM> for subsequent use.

Preferably, the cryopreserving temperature is below <NUM>. For example, the cryopreserving temperature may be below -<NUM>, -<NUM>, -<NUM>, -<NUM> or in liquid nitrogen or liquid helium, carbon dioxide ('dry-ice'), or slurries of carbon dioxide with other solvents. In some preferred embodiments, the cryopreserving temperature is about - <NUM>, about -<NUM> or about -<NUM>.

The method of the invention may additionally comprise the step of cryopreserving or freezing the substance. The cryopreserving or freezing of the substance may take place in the composition or before the substance is contacted with or placed in the composition. In other words, the substance may be frozen before it is contacted with the composition. As used herein, the term "freezing" or "frozen" refers to reducing the temperature to a cryopreserving temperature or being at a cryopreserving temperature.

In general, the substance will be placed in the composition and then the temperature will be reduced. It may be reduced directly to the final cryopreserving temperature or first to an intermediate temperature (which may be above or below the final cryopreserving temperature).

The rate of the freezing step may, for example, be slow (e.g. <NUM>-<NUM>/minute), or fast (above <NUM>/min). The rate of freezing may be at least <NUM>/minute, preferably at least <NUM>/minute, at least <NUM>/minute or at least <NUM>/minute. The rate of freezing may be between <NUM>/minute and <NUM>/minute, between <NUM>/minute and <NUM>/minute, or between <NUM>/minute and <NUM>/minute.

Fast rates of freezing may induce the production of ice crystals in the composition. Crystals produced in this way are small; they are also generally numerous. Upon warming or thawing of the cryopreserved composition, it has been found that the presence of poly(proline) in the composition inhibits the natural recrystallisation of these small ice crystals into larger ones, thus significantly reducing the cell death in biological material which would normally occur at this time.

The most preferred freezing rate in any one particular case will be dependent on the volume of the composition and the nature of the substance. By following the teachings herein and the above points in particular, the skilled person may readily determine the most appropriate freezing rate in any one case.

In general, the substance will initially be at a temperature about <NUM>, e.g. at about <NUM> or at ambient temperature. From there, its temperature will be reduced to the cryopreserving temperature, preferably in a single, essentially uniform step (i.e. without a significant break).

Rapid freezing using solid CO<NUM> slurries or liquid N<NUM> are preferred, which cool at approximately <NUM>/min. It is also possible to achieve similar rates using other cryogens which have a temperature which is colder than standard refrigerators (e.g. below -<NUM>).

Preferably, the substance or composition comprising the substance is not stirred and/or is not agitated during the freezing step.

The method of the invention may additionally comprise the step of warming or thawing the cryopreserved substance. The term "thawing" refers to raising the temperature of the cryopreserved substance (e.g. biological material) to <NUM> or above, preferably to <NUM> or above. The term "thawing" may also refer to raising the temperature of the cryopreserved substance to a temperature at which there are no or substantially no ice crystals in all or part of the cryopreserved substance. Hence the term "thawing" includes complete and partial thawing.

The substance may subsequently be isolated or removed from the composition. The term "recrystallization" is known in the context of cryopreservation to refer to the growth of existing ice crystals during the warming or thawing or a cryopreserved substance or product.

The term "recrystallization" may be contrasted with the term "nucleation" which relates to the formation of new ice crystals.

The rate of thawing may, for example, be slow (e.g. <NUM>-<NUM>/minute) or fast (above <NUM>/min). In some cases it may be advantageous to thaw slowly. Rapid thawing in a water bath at <NUM> is preferred. Cell recovery is also possible at lower temperatures (e.g. <NUM>).

Alternatively, the temperature of the cryopreserved substance may be raised to a temperature at which the cryopreserved substance may be removed from or isolated from the composition (e.g. <NUM> or above); and the substance may then be stored at this temperature until use.

Ice may be present in the cryopreserved substance at one or more stages during thawing of the cryopreserved substance.

Ice nucleation within the cryopreserved substance may be tested for by differential scanning calorimetry or cryomicroscopy.

The substance may be cryopreserved at a rate which induces the production of ice crystals, most preferably small ice crystals, in the cryopreserved substance. As used herein, the term "small ice crystals" means that the ice crystals are less than <NUM> in length, more preferably less than <NUM> in length, and most preferably less than <NUM>, less than <NUM>, less than <NUM> or less than <NUM> in length. Length refers to the longest dimension of the ice crystal. Preferably, at least <NUM>% of the ice crystals in the cryopreserved substance are less than <NUM> in length.

Most preferably, at least <NUM>% of the ice crystals in the cryopreserved substance are less than <NUM> in length. Most preferably, at least <NUM>% of the ice crystals in the cryopreserved substance are less than <NUM> or less than <NUM> in length. The percentages of ice crystals in the cryopreserved substance having less than a specified size may be determined by optical or electron microscopy.

Cryopreserved biological material may be stored for cell, tissue and/or organ banking. The cryopreserved substance may be stored at the cryopreserving temperature for any desired amount of time. Preferably, it is stored for at least one day, at least one week or at least one year. More preferably, it is stored for <NUM>-<NUM> days, <NUM>-<NUM> months or <NUM>-<NUM> years. In some embodiments, it is stored for less than <NUM> years.

After cryopreservation, biological material may be used for any suitable use, including human and veterinary uses. Such uses include for tissue engineering, gene therapy and cellular implantation and are not part of the present invention.

Also provided is a method of the invention wherein the substance is a biological material which is or has been pretreated with a composition comprising proline (monomers) before it is treated with a composition comprising poly(proline), or a variant or derivative thereof as defined in claim <NUM>. In such methods, proline increases cell viability.

Preferably, the biological material is pretreated with proline for <NUM>-<NUM> hours, more preferably about <NUM> hours.

The concentration of proline is preferably selected so as to help maintain the desired osmotic pressure within the cells of the biological material. In some embodiments it will be about <NUM> proline.

Preferably, the pre-treatment with proline is carried out in the absence of DMSO. Homo-polypeptides can be prepared via solid-phase synthesis [<NUM>], solution-phase polymerization (N-carboxyanhydrides [<NUM>] or condensation) or by recombinant methods [<NUM>]. One example using solid-phase peptide synthesis is given in Example <NUM>.

In some embodiments, the invention provides a frozen food product, wherein the frozen food product comprises poly(proline) or a variant or derivative thereof as defined in claim <NUM>. Preferably, the frozen food product has been infused, perfused or admixed with poly(proline) or a variant or derivative thereof.

Preferably, the frozen food product comprises ice cream, meat, a fruit or a vegetable.

The present invention is further illustrated by the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only.

Data were analysed with a one-way analysis of variance (ANOVA) on ranks followed by comparison of experimental groups with the appropriate control group (Holm-Sidak method) followed by Tukey's post hoc test. Excel <NUM> (Microsoft, Redmond, WA) and R (R Foundation for Statistical Computing, Vienna, Austria) were used for the analyses. Data sets are presented as mean ± (SEM).

To obtain polyproline of different molecular weights, a range of synthetic methods were employed. Oligo-proline of DP <NUM> (PPro<NUM>) and DP <NUM> (PPro<NUM>) were prepared by solid-phase peptide synthesis, alongside a high molecular weight commercial sample. L, D, and D/L (racemic) polyproline were synthesized by condensation polymerization using <NUM>-ethyl-<NUM>-(<NUM>-dimethylaminopropyl) carbodiimide (EDC, <FIG>). Following dialysis to remove excess amino acids, coupling reagents and low molecular weight fractions, the polymers were characterized by SEC (size exclusion chromatography) and the results shown in Table <NUM>. This indicated molecular weights in the region of ~<NUM>. mol-<NUM> and less disperse than expected due to fractionation during dialysis, and the rigid-rod like nature of the PPII helix which affects its SEC behaviour. Table <NUM> also contains polymers from previous work, which are included for later critical IRI activity analysis (vide infra).

Circular dichroism spectroscopy (CD) confirmed that PPro<NUM> adopted a PPII helix (<FIG>), compared to a standard (ESI, <FIG>) [<NUM>]. PPII (in CD) can be confused with a random coil. However, the characteristic signals associated with a PPII helix are present at <NUM> and <NUM>, whilst a random conformation exhibits slight peak shifting, with signals absent in the <NUM> region [<NUM>]. P(D)Pro<NUM> gave the mirror spectrum as expected for D-amino acids, whilst the D/L racemic mixture showed essentially no secondary structure.

L- and D-proline, poly-L-proline mol wt <NUM>,<NUM>-<NUM>,<NUM> (PPro<NUM>-<NUM>), ethyl (hydroxyimino) cyanoacetate (OxymaPure™), N-(<NUM>-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI), dichloromethane (DCM), phosphate-buffered saline preformulated tablets, and hydrochloric acid (<NUM>%) were purchased from Sigma Aldrich Co. (Gillingham, UK) and used without further purification. Dialysis Membrane Spectra/Por <NUM> Flexible <NUM> FWT <NUM> MWCO <NUM>/cm was purchased from Fischer Scientific (Loughborough, UK) and used directly. Phosphate-buffered saline (PBS) solution was prepared using preformulated tablets in <NUM> of Milli-Q water (><NUM>Ω mean resistivity) to give [NaCl] = <NUM>, [KCl] = <NUM>, and pH <NUM>. PPro<NUM> and PPro<NUM> (><NUM>%) were purchased bespoke from Peptide Protein Research Ltd (Fareham, UK) and were used without further purification. PPro<NUM>: m/z (ESI) <NUM> (<NUM>%, -<NUM>); PPro<NUM>: m/z (ESI) <NUM> (<NUM>%, +<NUM>), <NUM> (<NUM>%, +<NUM>), <NUM> (<NUM>%, +<NUM>).

SEC (size exclusion chromatography) was acquired a DMF Agilent <NUM>-LC MDS instrument equipped with differential refractive index (DRI), viscometry (VS), dual angle light scatter (LS) and dual wavelength UV detectors. The system was equipped with <NUM> x PLgel Mixed D columns (<NUM> x <NUM>) and a PLgel <NUM> guard column. The eluent was DMF with <NUM> mmol NH4BF4 additive. Samples were run at <NUM>/min at <NUM>. Poly(methyl methacrylate) standards (Agilent EasyVials) were used for calibration. Analyte samples were filtered through a nylon membrane with <NUM> pore size before injection. Respectively, experimental molar mass (Mn,SEC) and dispersity (Ð) values of synthesized polymers were determined by conventional calibration (relative to poly(methyl methacrylate) standards) using Agilent GPC/SEC software. Refractive index was recorded.

EDCI (<NUM>, <NUM> mmol) was dissolved in dry DCM (<NUM>) and stirred at room temperature under a flow of nitrogen for <NUM> minutes, followed by cooling to <NUM>. Within <NUM> minutes of cooling, L-proline (<NUM>, <NUM> mmol, <NUM> eqv) and OxymaPure™ (<NUM>, <NUM> mmol, <NUM> eqv) were added together to the reaction mixture, resulting in an instantaneous colour change to yellow. The mixture was stirred on ice under nitrogen for <NUM> further hour, and then warmed to RT with stirring overnight. The dark yellow solution was condensed in vacuo, dissolved in Milli-Q water (<NUM>) acidified to pH <NUM>-<NUM> with <NUM> HCI, and a minimum volume of methanol added until residual solids dissolved. Dialysis (> <NUM> kDa) for <NUM> hours was subsequently performed with regular water changes. The resulting solution was freeze dried, yielding an off-white solid. <NUM> (<NUM>%). The DL racemate, P(DL)Pron, utilised a <NUM>:<NUM> ratio of L- and D-proline (<NUM> mmol prolines).

A series of peptides were tested for IRI activity using a SPLAT assay [<NUM>]. Briefly, this involved seeding a large number of small ice crystals, which were annealed for <NUM> minutes at -<NUM>, before being photographed. The average crystal size was then measured, relative to a PBS control, with smaller values indicating more IRI activity, <FIG>/1C.

All peptides displayed a dose-dependent activity relationship with grain size reducing as concentration increased. Only weak molecular weight dependence was observed in the range tested. Example micrographs of a PPro<NUM>-<NUM> ice wafer compared to a PBS control are shown in <FIG>/1E, demonstrating potent inhibition. This activity was unexpected as most synthetic macromolecules show little or no IRI [<NUM>, <NUM>, <NUM>]. The shortest peptides (PPro<NUM>) lost activity below <NUM>. mL-<NUM>, but the longer polymers retained activity down to <NUM>. The magnitude of this activity is significantly weaker than AF(G)Ps which function at concentrations as low as <NUM>µg. mL-<NUM> [<NUM>], but comparable to polyampholytes which have found application in cellular cryopreservation [<NUM>-<NUM>].

Ice recrystallisation inhibition (IRI) activity was measured using a modified splat assay [<NUM>]. A <NUM>µL sample of polymer dissolved in PBS buffer (pH <NUM>) was dropped <NUM> onto a chilled glass coverslip, resting on a thin aluminium block placed on dry ice. Upon hitting the coverslip, a wafer with diameter of approximately <NUM> and thickness <NUM> was formed instantaneously. The glass coverslip was transferred onto the Linkam cryostage and held at -<NUM> under N<NUM> for <NUM> minutes. Photographs were obtained using an Olympus CX <NUM> microscope with a UIS-<NUM>20x/<NUM>/∞/<NUM>-<NUM>/FN22 lens and crossed polarizers (Olympus Ltd, Southend-on-Sea, UK), equipped with a Canon DSLR 500D digital camera. Images were taken of the initial wafer (to ensure that a polycrystalline sample had been obtained) and again after <NUM> minutes. Image processing was conducting using Image J, which is freely available. In brief, five of the largest ice crystals in the field of view were measured and the single largest length in any axis recorded. The average (mean) of these five measurements was then calculated to find the largest grain dimension along any axis. This was repeated for three individual wafers, and the average (mean) of these three values was calculated to give the mean largest grain size (MLGS). The average value was compared to that of a PBS buffer negative control.

Earlier work by Knight [<NUM>] observed that poly(hydroxyproline) had potent IRI activity, which was assumed to be due, in part, to the regularly spaced hydroxyl groups along the backbone. However, the observations made here suggest that it is the specific helical structure of poly(proline), rather than hydroxyl groups, which gives rise to the observed activity.

<FIG> shows a comparison of the IRI activity of poly(hydroxyproline) versus PPro<NUM> and, two other alpha-helical poly(amino acids) [<NUM>]. These alpha-helical controls, poly(lysine) (PLys<NUM>) and poly(glutamic acid) (PGlu<NUM>), showed no IRI, similar to PEG, which was used as negative control.

P(D)Pro<NUM> and P(DL)Pro<NUM> had statistically identical activity to PPro<NUM>, ruling out any stereospecific effects. This may suggest that the local structure around the amide bond, and not the stereochemistry or folding, is crucial as opposed to long-range order (which may still have a contribution, however).

It is hypothesised that IRI activity requires a balance between hydrophilic and hydrophobic domains for activity (amphipathy) [<NUM>, <NUM>]. PPro<NUM> was compared to that of a non-glycosylated Type I sculpin antifreeze protein (AFP) [<NUM>] and also against PGlu<NUM>, by mapping their hydrophobic/hydrophilic domains (<FIG>).

NMR solution phase (AFP Sculpin) and X-ray crystal structures of proteins and peptides of interest were acquired from the Protein Data Bank and other publically accessible sources, or computationally modelled in-house (PPro<NUM> and PGlu<NUM>). Structures were rendered in PyMOL (Schrödinger LLC, Cambridge, MA), which is freely available for educational use, and surfaces on the structures were displayed. An open source script "color_h" was used to colour the protein surface according to the Eisenberg hydrophobicity scale of its constituent amino acids, from red (hydrophobic) to white (hydrophilic). For the homo-polypeptides where scaling is not possible, aliphatic hydrogen and carbon were defined as hydrophobic whilst oxygen, hydrogen and nitrogen as hydrophilic, utilising the same colour scheme. Due to the lack of hydrogen bond donors in a PPro<NUM> PPII helix, this was considered representative.

Type I sculpin AFP (<FIG>) clearly possesses a segregated domain structure with regular 'patches' of hydrophobic/hydrophilic groups. PPro<NUM> (<FIG>) also possesses this facial amphiphilicity, with 'hydrophilic pockets' visible between the mostly hydrophobic polypeptide. In comparison, PGlu<NUM> (<FIG>, no IRI activity) has charged hydrophilic groups protruding from around the core of the helix, which prevents the presentation of core hydrophobic domains. This agrees with our previous study on Nisin A, which has pH-dependant IRI associated with segregated domains [<NUM>] and also of amphiphiles developed by Capicciotti et al. [<NUM>], which only function below the CMC (critical micelle concentration) [<NUM>].

A549 (human Caucasian lung carcinoma) cells were employed as prototypical adherent cell monolayer which are challenging to cryopreserve by traditional methods [<NUM>]. Rather than traditional DMSO-only cryopreservation, the protective osmolyte proline (which has no IRI activity unlike the polymer - see ESI) was also added; proline accumulates under water stress in some organisms, and aids the cryopreservation process [<NUM>-<NUM>]. A549 cells were incubated with <NUM> (<NUM>. mL-<NUM>) proline or media alone for <NUM> hours. The solution was then removed and replaced with <NUM> % DMSO with PPro<NUM> (<NUM>. mol-<NUM>, Ð =<NUM>). After <NUM> minutes exposure, all excess solvent was removed, before controlled freezing at <NUM>. min-<NUM> to -<NUM>, <FIG>. Following storage at -<NUM>, cells were thawed by addition of warm media and the total number of viable cells assessed via trypan blue <NUM> hours post-thaw.

<FIG> shows that using DMSO, the current 'gold' standard for cryopreservation, lead to just <NUM>% of the frozen cells being recovered. It was also observed that addition of poly(proline) to <NUM>% DMSO also failed to give any additional protection. However, cells which had been pre-conditioned with <NUM> proline for <NUM> then treated with <NUM>. mL-<NUM> PPro<NUM> and <NUM>% DMSO dramatically increased recovery of viable cells to <NUM>%. Increasing the concentration of poly(proline) beyond <NUM>. mL-<NUM> did not increase recovery further, as reported for other IRI's [<NUM>]. This is an unprecedented improvement in recovery for a macromolecular antifreeze and demonstrated the successful, rational, design, characterisation and application of a simplistic antifreeze protein mimic.

Human Caucasian lung carcinoma cells (A549) were obtained from the European Collection of Authenticated Cell Cultures (Salisbury, UK) and grown in <NUM><NUM> cell culture Nunc flasks (Corning Incorporated, Corning, NY, USA). Standard cell culture medium was composed of Ham's F-<NUM> (Kaighn's) Medium (F-<NUM>) (Gibco, Paisley, UK) supplemented with <NUM>% USA-origin foetal bovine serum (FBS) purchased from Sigma Aldrich Co Ltd (Gillingham, UK), <NUM> units/mL penicillin, <NUM>µg/mL streptomycin, and <NUM> ng/mL amphotericin B (PSA) (HyClone, Cramlington, UK). A549 cells were maintained in a humidified atmosphere of <NUM>% CO<NUM> and <NUM>% air at <NUM> and the culture medium was renewed every <NUM>-<NUM> days. The cells were subcultured every <NUM> days or before reaching <NUM>% confluency. To subculture, cells were dissociated using <NUM>% trypsin plus <NUM> EDTA in balanced salt solution (Gibco) and reseeded at <NUM>. 87X10<NUM> cells per <NUM><NUM> cell culture flasks.

Solutions for cell incubation experiments were prepared by dissolving the individual compounds in F-<NUM> supplemented with <NUM>% FBS and 1X PSA (solutions used as freezing buffers did not contain PSA) and sterile filtered prior to use.

Claim 1:
A method of preventing or inhibiting ice recrystallization in a substance which is susceptible to ice crystal growth upon cryopreservation and/or warming or thawing therefrom, the method comprising the step:
(i) treating the substance with a composition comprising poly(proline) or a variant or derivative thereof,
wherein the poly(proline) or a variant or derivative thereof is a homogeneous or heterogeneous mixture of polymers which consist substantially or exclusively of linear chains of proline residues, the polymers having the general structure:
<CHM>
wherein n = <NUM>-<NUM>; preferably <NUM>-<NUM> or <NUM>-<NUM>; more preferably <NUM>-<NUM>, <NUM>-<NUM> or <NUM>-<NUM>; and even more preferably <NUM>-<NUM> or <NUM>-<NUM>.